This image provided by Guardant Health in March 2024, shows packaging for their colon cancer blood test, Shield. According to a study published Wednesday, March 13, 2024, in the New England Journal of Medicine and sponsored by Guardant Health, the test performed well, further expanding screening options for a leading cause of cancer deaths. The test missed some cancers and wont replace colonoscopy, the gold standard test.
“The best test is the one someone will actually complete,” said Dr. Douglas Corley, chief research officer for Kaiser Permanente, Northern California, who was not involved in the study. “Giving people a choice increases the number of people who will get screened.” The study, sponsored by Guardant and published in the New England Journal of Medicine, involved 7,861 people in the U.S. who had both a colonoscopy and a blood test.
The blood test is tuned to pick up the signature of colon cancer but more research is needed to determine if it might pick up other cancers as well and give misleading results, Corley said.is the second leading cause of cancer deaths in the United States and the third worldwide. In the U.S., more than 153,000 new cases and 53,000 deaths from the disease are expected this year.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MedicineNet - 🏆 575. / 51 Read more »
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: MedicineNet - 🏆 575. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: usweekly - 🏆 390. / 55 Read more »
Source: Health - 🏆 396. / 53 Read more »